(Q42949033)

English

Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma

scientific article published on August 2, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma (English)

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

1 reference

based on heuristic

inferred from title

Kunio Matsumoto

4

object named as

Kazuko Matsumoto

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20679350

15 June 2024

author name string

Kazuo Kasahara

1

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Tokuzo Arao

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Kazuko Sakai

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Asao Sakai

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Hideharu Kimura

6

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Takashi Sone

7

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Atsushi Horiike

8

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Makoto Nishio

9

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Tatsuo Ohira

10

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Norihiko Ikeda

11

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Takeharu Yamanaka

12

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Nagahiro Saijo

13

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Kazuto Nishio

14

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

language of work or name

0 references

publication date

2 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

full work available at URL

http://clincancerres.aacrjournals.org/content/16/18/4616.full.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20679350

15 June 2024

http://clincancerres.aacrjournals.org/cgi/content/abstract/16/18/4616

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20679350

15 June 2024

https://aacrjournals.org/clincancerres/article-pdf/16/18/4616/1991890/4616.pdf

Portable Document Format

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

4616-4624

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1126/SCIENCE.1141478

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/J.CCR.2009.11.022

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells

3

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

4

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Erlotinib in previously treated non-small-cell lung cancer

5

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

6

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

7

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

8

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.

9

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

10

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

11

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

12

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

13

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Mutations and response to epidermal growth factor receptor inhibitors

14

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib

15

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

16

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers

17

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET

19

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

The MET receptor tyrosine kinase in invasion and metastasis

20

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

The Met tyrosine kinase receptor in development and cancer

21

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

22

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.

23

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas

24

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma

25

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection

26

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy

27

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma

28

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

30

1 reference

10.1158/1078-0432.CCR-10-0383

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0383

15 June 2024

Identifiers

10.1158/1078-0432.CCR-10-0383

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42949033&oldid=2182204184"